Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001

Valneva announced that the European Commission (EC) has granted marketing authorization in Europe for Valneva‚Äôs inactivated whole-virus COVID-19 vaccine, VLA2001, for use as primary vaccination in people from 18 to 50 years of age.

Read more